Neurogene Inc. (NGNE) Form 8-K — Aug 11, 2026
Neurogene reported second quarter 2026 results headlined by long-term Phase 1/2 data for NGN-401 in Rett syndrome showing 100% of participants (N=10) improved on the CGI-I scale and gained at least one developmental milestone, averaging 4.7 milestones per participant with no plateau or milestone loss through up to 30 months of follow-up. The company completed dosing of all 25 participants in its Embolden registrational trial — overenrolled by 25% on community demand — and expects topline data in the second half of 2027, with BLA-enabling PPQ runs completing by year-end 2026.
Key figures
- Cash Position
- 225400000
- Dose level
- 1E15 vg
- Rsgms gain
- 5.2-point increase vs. 0.8-point natural-history decrease (p<0.001)
- Cash runway
- into the first quarter of 2029
- Ppq completion
- by end of 2026
- Pro forma cash
- approximately $360.2 million
- Net loss q2 2025
- 22000000
- Ga expense q2 2025
- 6700000
- Ga expense q2 2026
- 11200000
- Rd expense q2 2025
- 19400000
- Rd expense q2 2026
- 25500000
- Topline data timing
- 2H 2027
- Phase12 participants
- 10
- Follow on net proceeds
- 134800000
- Total milestones gained
- 47
- Follow on gross proceeds
- approximately $144 million
- Embolden success threshold
- 33% (8 of 24)
- Embolden participants dosed
- 25
- Median time to first response
- 2 months
- Phase12 composite responder rate
- 80% (8 of 10) at 12 months
- Total safety database participants
- 35
- Avg developmental milestones per participant
- 4.7
Price after filing
Close on the filing date to close N calendar days later (from $35.69). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.